Outcome predictors for maternal red blood cell alloimmunisation with anti-K and anti-D managed with intrauterine blood transfusion.
alloimmunisation
intrauterine transfusion
pregnancy
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
29
10
2021
received:
15
08
2021
accepted:
30
10
2021
pubmed:
5
12
2021
medline:
3
3
2022
entrez:
4
12
2021
Statut:
ppublish
Résumé
Red blood cell (RBC) alloimmunisation with anti-D and anti-K comprise the majority of cases of fetal haemolytic disease requiring intrauterine red cell transfusion (IUT). Few studies have investigated which haematological parameters can predict adverse fetal or neonatal outcomes. The aim of the present study was to identify predictors of adverse outcome, including preterm birth, intrauterine fetal demise (IUFD), neonatal death (NND) and/or neonatal transfusion. We reviewed the records of all pregnancies alloimmunised with anti-K and anti-D, requiring IUT over 27 years at a quaternary fetal centre. We reviewed data for 128 pregnancies in 116 women undergoing 425 IUTs. The median gestational age (GA) at first IUT was significantly earlier for anti-K than for anti-D (24·3 vs. 28·7 weeks, P = 0·004). Women with anti-K required more IUTs than women with anti-D (3·84 vs. 3·12 mean IUTs, P = 0·036) and the fetal haemoglobin (Hb) at first IUT was significantly lower (51.0 vs. 70.5 g/l, P = 0·001). The mean estimated daily decrease in Hb did not differ between the two groups. A greater number of IUTs and a slower daily decrease in Hb (g/l/day) between first and second IUTs were predictive of a longer period in utero. Earlier GA at first IUT and a shorter interval from the first IUT until delivery predicted IUFD/NND. Earlier GA and lower Hb at first IUT significantly predicted need for phototherapy and/or blood product use in the neonate. In the anti-K group, a greater number of IUTs was required in women with a higher titre. Furthermore, the higher the titre, the earlier the GA at which an IUT was required in both groups. The rate of fall in fetal Hb between IUTs decreased, as the number of transfusions increased. Our present study identified pregnancies at considerable risk of an unfavourable outcome with anti-D and anti-K RBC alloimmunisation. Identifying such patients can guide pregnancy management, facilitates patient counselling, and can optimise resource use. Prospective studies can also incorporate these characteristics, in addition to laboratory markers, to further identify and improve the outcomes of these pregnancies.
Substances chimiques
RHO(D) antibody
0
Rho(D) Immune Globulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1096-1104Informations de copyright
© 2021 British Society for Haematology and John Wiley & Sons Ltd.
Références
van Klink JM, Koopman HM, Oepkes D, Walther FJ, Lopriore E. Long-term neurodevelopmental outcome after intrauterine transfusion for fetal anemia. Early Human Dev. 2011;87:589-93.
Lindenburg IT, Smits-Wintjens VE, van Klink JM, Verduin E, van Kamp IL, Walther FJ, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol. 2012;206:141.e1-8.
Phung TV, Houfflin-Debarge V, Ramdane N, Ghesquière L, Delsalle A, Coulon C, et al. Maternal red blood cell alloimmunization requiring intrauterine transfusion: a comparative study on management and outcome depending on the type of antibody. Transfusion. 2018;58:1199-205.
Ghesquière L, Garabedian C, Coulon C, Verpillat P, Rakza T, Wibaut B, et al. Management of red blood cell alloimmunization in pregnancy. J Gynecol Obstet Hum Reprod. 2018;47:197-204.
Das S. Hemolytic disease of the fetus and newborn. In Tombak A, editor, Blood Groups. IntechOpen, 2019. Available at: https://www.intechopen.com/chapters/67168. Accessed November 2021.
Tovey LA. Haemolytic disease of the newborn-the changing scene. Br J Obstet Gynaecol. 1986;93:960-6.
Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med. 2008;13:207-14.
Kahar MA, Patel RD. Phenotype frequencies of blood group systems (Rh, Kell, Kidd, Duffy, MNS, P, Lewis, and Lutheran) in blood donors of south Gujarat, India. Asian J Transfus Sci. 2014;8:51-5.
Santiago JC, Ramos-Corpas D, Oyonarte S, Montoya F. Current clinical management of anti-Kell alloimmunization in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2008;136:151-4.
de Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the fetus and newborn. Vox Sang. 2015;109:99-113.
Gariod S, Brossard Y, Poissonnier MH, Vuilliez B, Deutsch V, Jouk PS, et al. Kell alloimmunization in pregnancy. J Gynecol Obstet Biol Reprod. 2004;33:637-48.
Gajjar K, Spencer C. Diagnosis and management of non-anti-D red cell antibodies in pregnancy. Obstet Gynaecol. 2011;11:89-95.
McKenna DS, Nagaraja HN, O’Shaughnessy R. Management of pregnancies complicated by anti-Kell isoimmunization. Obstet Gynecol. 1999;93:667-73.
Tuson M, Hue-Roye K, Koval K, Imlay S, Desai R, Garg G, et al. Possible suppression of fetal erythropoiesis by the Kell blood group antibody anti-Kp(a). Immunohematology. 2011;27:58-60.
Vaughan JI, Manning M, Warwick RM, Letsky EA, Murray NA, Roberts IA. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med. 1998;338:798-803.
Weiner CP, Widness JA. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Am J Obstet Gynecol. 1996;174:547-51.
Daniels G, Hadley A, Green CA. Causes of fetal anemia in hemolytic disease due to anti-K. Transfusion. 2003;43:115-6.
Vaughan JI, Warwick R, Letsky E, Nicolini U, Rodeck CH, Fisk NM. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. Am J Obstet Gynecol. 1994;171:247-52.
Grant SR, Kilby MD, Meer L, Weaver JB, Gabra GS, Whittle MJ. The outcome of pregnancy in Kell alloimmunisation. BJOG. 2000;107:481-5.
Koelewijn JM, Vrijkotte TG, Van Der Schoot CE, Bonsel GJ, de Haas M. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion. 2008;48:941-52.
Kapur R, Della Valle L, Sonneveld M, Hipgrave Ederveen A, Visser R, Ligthart P, et al. Low anti-RhD IgG-Fc-fucosylation in Pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. Br J Haematol. 2014;166:936-45.
Liley AW. Liquor amnil analysis in the management of the pregnancy complicated by resus sensitization. Am J Obstet Gynecol. 1961;82:1359-70.
Abbasi N, Johnson JA, Ryan G. Fetal anemia. Ultrasound Obstet Gynecol. 2017;50:145-53.
Garabedian C, Rakza T, Thomas D, Wibaut B, Vaast P, Subtilet D, et al. Neonatal outcome after fetal anemia managed by intrauterine transfusion. Eur J Pediatr. 2015;174:1535-9.
Rocha G, Pereira S, Antunes-Sarmento J, Flôr-de-Lima F, Soares H, Guimarães H. Early anemia and neonatal morbidity in extremely low birth-weight preterm infants. J Matern Fetal Neonatal Med. 2021;34:3697-3703.
Sánchez-Durán M, Higueras MT, Halajdian-Madrid C, Avilés García M, Bernabeu-García A, Maiz N, et al. Management and outcome of pregnancies in women with red cell isoimmunization: a 15-year observational study from a tertiary care university hospital. BMC Pregnancy Childbirth. 2019;19:356.
Slootweg YM, Lindenburg IT, Koelewijn JM, Van Kamp IL, Oepkes D, De Haas M. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. Am J Obstet Gynecol. 2018;219:393.e1-8.
Koelewijn JM, Slootweg YM, Folman C, van Kamp IL, Oepkes D, de Haas M. Diagnostic value of laboratory monitoring to predict severe hemolytic disease of the fetus and newborn in non-D and non-K-alloimmunized pregnancies. Transfusion. 2020;60:391-9.